Gut microbiome plays a crucial role in the building-up of our immunity system at birth. It is a life-long personal and natural protection but increasing evidence suggests that dysregulated immune responses against commensal microbes in the gut are strongly involved in Inflammatory Bowel Diseases, Metabolic disorders, Oncology, Depression, Allergies amongst numerous diseases.

Enterome dedicates its activities to the development of innovative therapeutic approaches (drugs and biomarkers) to support a personalized medicine for microbiome-related diseases.


Crohn’s disease and other IBD such as Ulcerative Colitis, are chronic inflammatory diseases which affect over 3 million Americans and Europeans, most of whom are generally diagnosed before age 35. These chronic, life-long conditions have a major impact on patient’s quality of life.

Current medical treatment of CD consists of immunosuppressive drug therapy which control symptoms of CD in most patients, but their withdrawal leads to disease relapse and are also associated with serious side effects.

Our approach is based on an oral and non-systemic small molecule drug candidate that is designed to block FimH-mediated attachment of Adherent Invasive E Coli (AIEC) thereby preventing local inflammatory cytokine production and the entry of AIEC into the gut wall by selectively disarming the virulent bacteria without disrupting the gut microbiome.



Cancer is a disease caused by changes to genes that control the way our cells function, especially how they grow and divide ; and which has a major impact on society across the world.

Rationale behind cancer vaccination lies on delivering tumor antigens to patients and on targeting their dendritic cells, with the aim of inducing an efficient presentation of cancer epitopes to T lymphocytes and, consequently, boost a sustained immune response against cancer cells expressing the same antigens at the tumor site.

Our work on discovering and developing novel bacterial-derived cancer antigens that are expressed in human gut microbiome, and wish to provide new solutions to making cancer cells detectable by adoptive immune system and to boost their immunogenicity.



Autoimmune diseases develop when the immune system, natural body defense against disease, consider the healthy cells as foreign. Therefore this dysregulation of the immune system attack healthy cells. Autoimmune diseases can affect many different types of body tissue.

They affect at least 5% of the population.

In the absence of curative therapy, treatment for autoimmune diseases focuses only on relieving symptoms.


In 2016, Enterome has entered with BMS into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.

The collaboration will combine Bristol-Myers Squibb’s expertise in the discovery and development of novel immunotherapies with Enterome’s proprietary metagenomic technology platform and leadership in the rapidly advancing science of the gut microbiome to support the discovery of novel immunotherapy agents and biomarkers. There is a growing body of scientific evidence to suggest that the gut microbiome plays an important role in modulating mechanisms of response and resistance to cancer immunotherapies. Changes in a host’s immune system driven by the gut microbiome can be exploited to identify specific targets and bioactive compounds with the potential to augment anti-cancer immune responses.

In January 2016, Enterome has announced a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The agreement, facilitated by Johnson & Johnson Innovation, is focused on the discovery of novel targets and bioactive molecules from the gut microbiome for the potential development of therapeutic solutions to Crohn’s disease.

The collaboration aims to advance the characterization and therapeutic validation of these bacterial products, increase knowledge of the regulation of immunity and gut homeostasis, and potentially lead to the development of new therapeutic solutions for Crohn’s disease.

The Janssen Human Microbiome Institute will also join the collaboration to help accelerate the translation of microbiome science into therapeutic solutions in the area of Crohn’s disease.

In January 2016, Enterome has announced a strategic drug discovery collaboration with Takeda Pharmaceutical, to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).

In October 2018, Enterome has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.





VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma. Pierre is PharmD, PhD and holds a MBA from INSEAD.



Simon joined Enterome in September 2016. In his most recent role at Sanofi he has project-led and negotiated divestment of an R&D site, assumed Chief of Staff responsibility of a 150-headcount department, managed a 40M budget, and led several internal operational excellence and portfolio management initiatives across R&D with Comex level visibility. Prior to that, Simon has performed strategic projects across R&D, marketing and distribution scope at the Healthcare Practice of the Boston Consulting Group and managed a family-owned GP practice over a 1 year interim period. He holds a PhD of the University of Paris Descartes and a MSc of the University of Basel.




Christophe has 20 years’ experience in the field of molecular biology and signaling pathways, 15 years in the field of hit identification to candidate selection, has authored 80 scientific publications and is an inventor on 12 patent families. Before joining Enterome, Christophe was CSO at Bicycle Therapeutics. He discovered XG-102/AM-111 and XG-104, the two first clinical stage intracellular peptidic inhibitors of the JNK protein. These compounds, now in clinical phases 2 and 3, formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery. Christophe was CSO of Xigen SA and also served as its President for 6 years.




Business Development & Contract Manager at Sanofi, Marie-Laure joined Fovea Pharmaceuticals at inception as Business Development associate and has been involved in all licensing and contractual operations of the company from founding to trade sale to Sanofi. Earlier, Marie-Laure has been Business Development associate at UroGene.




Before joining Enterome, Rodolphe Clerval was VP Corporate and Business Development of TcLand Expression, a molecular diagnostic company. During his tenure with TcLand Expression, he led strategic planning activities and closed several collaborations and licensing deals. Previously he was Business Development Manager at Genzyme. Prior to this he was financial analyst for the brokerage firm Natixis Bleichroeder. Earlier in his career, Rodolphe served as Research Scientist at Aventis Animal Nutrition.




Christelle joined Enterome in November 2015 with more than 20 years of experience in financial departments of various industries. Lately, she worked in the services industries for public and private companies, focused on structuring the administrative and finance department and on securing the business development. She previously served as Finance Director at Fournier/Solvay Pharma. During these years, she was in charge of cross-functional projects regarding the reorganization of the new pharmaceutical division and acted during 4 years as CFO of the Belgian subsidiary. She has started her career as business analyst for mass market groups like Sara Lee and Diageo. Christelle holds a Master in Business Management from the ISC Paris.



Jan joined Enterome in January 2019 with more than 25 years of experience from clinical oncology and global oncology drug development. He has a MD and a PhD from the Karolinska Institute and is board-certified in medical oncology and radiotherapy. After 10 years of oncology practice and academic translational immuno-oncology research at the Karolinska Hospital, Jan joined Roche in 1999. Jan’s responsibilities were mainly related to capecitabine (Xeloda) and bevacizumab (Avastin) ultimately serving as Therapeutic Area Expert Oncology at Hoffmann-La Roche, Basel. Jan joined the Danish biotech TopoTarget A/S end of 2006 focusing on development of the HDACi belinostat (Beleodaq). Jan then led the Clinical Development Department at Micromet Inc./GmbH from end 2009 especially focusing on the clinical development of BiTEs and the lead compound blinatumomab (Blincyto). After this Jan has gained further immuno-oncology experience leading clinical development work with oncolytic viruses at Oncos Therapeutics Ltd, with synthetic peptide immunization at ISA Pharmaceuticals B.V. and with autologous dendritic cell immunization at SOTIO a.s. Jan has published more than 60 articles related to immuno-oncology/oncology in peer-reviewed journals, and is a member of the European Society for Medical Oncology and the American Society of Clinical Oncology.




Georges has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the US, Europe and the Middle East. He currently serves on the board of directors of US publicly-traded companies Supernus Pharmaceuticals, Inc. and Raptor Pharmaceutical Corp., and is the Chairman of the boards of OxThera AB, EpiTherapeutics ApS and Orphazyme ApS. From 2008 to 2009, Dr Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals Inc., a publicly-traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company’s global therapeutics, transplant, renal and biosurgery businesses. From 1998 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs, most recently as Vice President, National Specialty Care, responsible for its US business for dermatology, oncology, transplantation, hepatitis and HIV.




VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma. Pierre is PharmD, PhD and holds a MBA from INSEAD.



Johan Kördel has served as a member of our board of directors since March 2012. Before joining Lundbeckfonden Ventures in 2010, Johan worked 20 years in the pharma and biotech industry with structural biology, discovery, research management, early development, portfolio management, business development and alliance management. Johan was previously co-founder and CEO of Sound Biotech ApS and co-founder and Senior Vice President of Research as well as Business Development of Biovitrum AB. Prior to these positions he worked almost a decade in the pharmaceutical company Pharmacia. Johan has co-founded other biotech companies and been serving on numerous boards both in private and public life science companies. Johan trained as a Physical Chemist at University of Lund, Sweden, Scripps Research Institute, La Jolla, California and Harvard Medical School, Boston, Massachusetts. He is an associate professor in Physical Chemistry at the University of Lund, Sweden. Johan is a board member of Acacia Pharma, Enterome, Iconic Therapeutics and VHSquared



Isabelle de Cremoux has served as a member of our board of directors since 2008 and is CEO and Managing Partner of Seventure where she leads the Life Sciences team. Isabelle began her career in 1991 with Arthur Andersen in Detroit, USA. She then moved to Pfizer France and Pfizer Europe where she held various positions for six years within management, clinical research and business development. In 1998, Isabelle joined Laboratoire Fournier / Abbott as Deputy Director of Business Development, in charge of product and technology licensing and acquisitions, and signed numerous Europe and and USA deals. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field. Isabelle’s investment experiences include Santaris (sold to Roche for $450 million in August 2014), ArgenX (listed), OPI (sold to Eusa for € 110 million), Bioalliance (listed), Pixium vision (listed). She is currently responsible for Enterome Biosciences, Maat Pharma, Targedys, LNC, etc. Isabelle holds a degree in Engineering from l’Ecole Centrale Paris and brings more than 25 years of international business development and finance experience in the pharmaceutical industry to the team.



Martin Hendrix has served as a member of our board of directors since December 2018. Mr. Hendrix currently serves on the board of directors of Microbiome Diagnostic Partners, and is a board observer at Kaleido and Kintai. Until May 2018 he also served as a board observer of Evelo Biosciences.  Currently Mr. Hendrix serves as Vice President, Global Business Development, at Nestlé Health Science, a division of Nestlé S.A. Prior to joining Nestlé in 2012, Mr. Hendrix had a 14 year career at Bayer, with roles ranging from research to M&A and corporate development, including from 2008 to 2012, serving as Director of Strategy and Portfolio Management for Bayer Healthcare’s Specialty Medicine division.  Mr. Hendrix holds a Ph.D. from The Scripps Research Institute, and a Master of Science from the Georgia Institute of Technology. Mr. Hendrix was nominated to our board of directors by Nestlé S.A., the legal entity that has held this board seat since December 2017.



Andrea is an Entrepreneur, an active angel investor and a general partner at Principia SGR, the leading Venture Capital manager in Italy. He started his career in Italy as an Electronic Engineer designing satellite communication networks and later moved to the financial sector working in London at the Industrial Bank of Japan, Barclays Capital and Merrill Lynch. Seeing an opportunity in the rapid raise of the independent risk analysis function he founded Mangustarisk taking it to become the premier Italian risk management firm with over EUR 60 bn of asset under advice. He is particularly active in the bio-pharmaceutical and medical device spaces structuring direct investments and participations both through Principia’s dedicated funds and personally; he holds board positions in Italy, France and the UK and is an active shareholder in a series of business initiatives.



Pierre has over 25 years’ experience in leading organizations and high-growth-potential start-ups through the development and launch of innovative tests and high-science clinical diagnostic solution. He is currently President and Chief Executive Officer at NMS Labs. Before this, he was CEO at Molecular Diagnostic LTD, President and CEO, XDX Inc. Earlier, Pierre was VP Diabetes Management, Becton Dickinson, Senior VP Business Operations, Bayer US and BU General Manager, J&J.



Roger is Board certified pediatrician with 30 years Pharmaceutical Development, Global Regulatory and Medical Affairs experience. Experience in multiple successful FDA Advisory Committee meetings, EU Scientific advice and PDMA meetings. Roger has a broad experience in drugs, biologics and combination drug/device products for orphan and non-orphan indications, both in US and Internationally. Roger successfully built development and medical organizations from ground up. Roger recently led two successful orphan products through filing, Advisory Committees and registrations.



Mary brings extensive experience in the life sciences industry, serving in senior finance, operations and business development roles. She is currently Chief Operating Officer at Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology.Prior to joining Dimension in 2015, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals, significantly driving growth of the company’s pipeline prior to Cubist’s $9.5 billion acquisition by Merck & Co. (MSD outside the US). Prior to this, she held leadership positions at ViaCell, Inc. Ms. Thistle began her career in finance as a certified public accountant working with both private and public companies. She received her B.A. degree in accounting from the University of Massachusetts.





Maximilien joined Omnes Capital as Associate specialized in healthcare investments in the Venture Capital team.

Prior to that, Maximilien co-founded FeetMe, a medical device company that allows continuous monitoring and analysis of patient’s gait suffering from neurological disorders. He developed the product from strategy definition to commercial launch in Europe. He created and lead a cross functional team in charge of technical, clinical and regulatory affairs.

Besides Enterome, Maximilien represents Omnes Capital on the boards of Themis, Eye Tech Care and Gecko Biomedical. Maximilien graduated from Ecole Polytechnique and holds a MS in Bioengineering from the University of California Los Angeles (UCLA).





Two complementary metagenomic platforms
for a full genomic and functional analysis of the microbiome


based on full sequencing and mapping of total fecal bacterial gene content that allows the characterization of a personal metagenome (metagenotype®) associated with a disease phenotype. This technology enables the identification of biomarkers and of bacteria of interest associated with the development of diseases.


based on the screening of genomic or metagenomics libraries on cell based assays and on specific pathways of interest that allows the discovery and the development of news drugs and targets.





EB8018 is an oral and non-systemic small molecule drug that is designed to block FimH adhesin from overabundant Enterobacteriaceae in Crohn’s disease patients thereby preventing biofilm formation, lowering the local inflammatory cytokine production and impairing mucosa invasion and subsequent tissue damage.


Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract. Emerging evidence suggests that the microbiome plays an important role in triggering an abnormal mucosal immune response in patients with Crohn’s disease. Enterome has identified the FimH adhesin from overabundant Enterobacteriaceae in the gut microbiomes of patients suffering from Crohn’s disease as a potential novel target to block inflammation through application of its metagenomics platform.

EB8018 is designed to block FimH thereby preventing local cytokine production and the invasion of bacteria into the gut wall by selectively disarming the virulent bacteria without disrupting the gut microbiome. It represents a novel oral, non-biologic, non-steroidal, non-antibiotic, non-immunomodulatory and local approach for the treatment of Crohn’s disease. Enterome in-licensed EB8018 from Vertex Pharmaceuticals Inc. EB8018 successfully completes Phase Ia clinical study designed to determine the safety and tolerability profile of single and multiple doses of EB8018 in healthy volunteers and a Ph1b trial has been initiated. The Phase 2 clinical proof-of-concept trial with EB8018 is planned to start in 2019 together with Takeda Pharmaceutical through a global licensing, co-development and co-promotion agreement.


EB420 is a therapeutic program for the discovery of new drug candidates for the treatment of Inflammatory Bowel Diseases. Enterome and Takeda Pharmaceutical jointly collaborate for the development of new drug candidates for the treatment of severe GI disorders.


EB110 is a therapeutic program for the discovery of new drug candidates in Crohn’s Disease. Enterome and Johnson & Johnson jointly collaborate for the discovery of novel target and microbiome derived bioactive molecules.


IBD210 is a companion diagnostic related to EB8018, Enterome clinical stage drug candidate in Crohn’s disease. IBD210 enables to quantify FimH protein expression in fecal samples from patients.



Enterome is developing next-gen microbiome-derived cancer vaccines by targeting novel antigens called onco-mimics, -a set of antigens present in the microbiome of patients that are close “mimics” of tumor antigens. Onco-mimics work in combination with Check-Point Inhibitors to break immune self-tolerance, effectively helping CPIs destroying tumors, -in a way very much resembling how autoimmunity works at destroying normal cells and tissues. In effect, onco-mimics train the immune system to target and fight cancer cells as if they were fighting an infectious invasion from a bacteria. EO2401, the front-runner candidate of this program is currently in non-clinical development to treat patients with Glioblastoma Multiforme (GBM). Development in a second cancer indication is under preparation.


Vaccination is a very promising immunotherapeutic approach to advancing towards a cure for cancer. The rationale behind cancer vaccination lies on delivering tumor antigens together with adjuvants to patients to induce a sustained immune response against the cancer cells expressing the tumor antigen. However, using unmodified tumor antigens generally results in poor immunogenicity and lack of efficacy due to mechanisms based on self-tolerance. Enterome is discovering and developing novel bacterial microbiome-derived antigens resembling known tumor antigens in order to break self-tolerance and make cancer cells attacked by the adaptive immune system, resulting in an expected improvement in clinical outcomes. Based on the concept of molecular mimicry between bacterial and cancer epitopes, bacterial-derived antigens expressed in human gut microbiome are confronted using alignment tools with known human tumor antigen-derived peptides. 400+ bacterial-derived peptides have been identified through their high MHC affinity and are being investigated. The front-runner of this program is EO2401, consisting of several bacterial-derived peptides mimicking different known tumor antigens. EO2401 is currently in non-clinical development for treatment of Glioblastoma Multiforme (GBM), a highly aggressive solid neoplasm that is the most lethal form of brain tumor. Development in different cancer indications with a compatible multi-antigen signature is under preparation.  


EO520 is a therapeutic program for the discovery of new drug candidates for the treatment of cancer. Enterome and Bristol-Myers Squibb jointly collaborate for the discovery of novel biomarkers.



EO510 is a therapeutic program for the discovery of new drug candidates for the treatment of divers types of cancer such as glioblastoma, colon, pancreatic, lung and breast. This therapeutic program enables Enterome to discover microbiome related antigen mimics (« onco-mimics ») of cancer antigens.



Our company has been established in 2012 and has already raised a 63.8M€ in four rounds with private equity funds (Seventure, Omnes Capital, Lundbeckfonden, Health for Life Capital, Principia SGR) and strategic investors (INRA Transfert, Shire, Nestlé, BMS).


Being one of the leading venture capital firms in Europe, Seventure manages €500m and invests since 1997 in innovative businesses with high growth potential in IT and in Life Sciences. With preferred sectors of Biotech & Pharmaceuticals, Medtech, Industrial Biotech & Cleantech, and Lifestyle Healthcare & Nutrition. Seventure is a subsidiary of Natixis.


Lundbeckfonden Ventures is a life science venture fund established in 2009 and wholly owned by the Lundbeck Foundation. On an annual basis, Lundbeckfonden Ventures invests up to € 50 million. Investments are made within lifescience, focusing on pharmaceuticals and biopharmaceuticals, medtech, diagnostics and healthcare service companies.


Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €2.1 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, formerly Crédit Agricole Private Equity, was a subsidiary of Crédit Agricole until March 2012 when the company was acquired by Coller Capital.


Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and its partners in healthcare. Nestlé Health Science’s portfolio of nutrition solutions, diagnostics, devices and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide. For more information, please visit: www.nestlehealthscience.com.


Health for Life Capital supports innovative high-growth entrepreneurial ventures. Geographically, its focus is primarily in Europe, but also extends to North America and Asia. Investments will be made in the areas of healthcare, life sciences, biotechnology, medical technologies, pharmaceuticals, nutrition and in the emerging fields of microbiome and connected health.


Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.


Principia SGR, founded in 2002, is one of the leading Italian venture capital operators. The SGR currently manages 4 investment fund: Principia II, Principia III – Health, Principia IV – Alis and Principia V Utopia. The fund Principia III – Health, dedicated to Venture and Growth capital investments in the Healthcare sector, raised 206 million euros, and made 9 investments as of today deploying 80 million euros. Principia IV – Alis is the fourth Fund of the SGR dedicated to the development of the excellence of Made in Italy, focused on fashion and design. The fund it is currently in fund raising. Principia Utopia is the most recent Fund launched by Principia with a target size of €70 million. The Fund has a very well-defined strategy: funding and supporting Life-Tech start ups for patents development in the first and second stage with management of the intellectual property. The focus will be on projects that develop molecules, curative devices and advanced diagnostics for prevention.


We are an innovation-driven company with a strong team spirit as well as a great place to work where you can get things to move.

Working in lean teams for a human-size company, you will get a real mission with objectives to fulfil : flexibility and scope of action is wide, and learning becomes a daily routine.

Also, you will get a chance to quickly take ownership and increase your responsibilities.

The solutions we deliver are the sum of our collective talents, and we believe the best results arise from integrating a mix of perspectives and experiences.

Furthermore, as you get involved and enjoy what you do, we make sure you get recognition for your achievements.

We need enthusiastic and passionate new hires to take on challenges and develop our business.

If you wish to acquire key competencies and to develop them, Enterome is the place to be.

If you have a positive, proactive, startup mentality, and are interested in joining a highly disruptive life science business on the forefront of the burgeoning microbiome industry:



We are currently expanding our Immuno-Oncology department and are looking for new talented people to join our team from leadership positions to research and development functions.

Apply now and become part of an amazing adventure in Life Sciences at Enterome.



94/96 avenue Ledru-Rollin 75011 Paris – France
Tel : +33 (0)1 75 77 27 85

Lab facilities

Biocluster Genopole – 5 rue Henri Desbruères – 91030 Evry Cedex



One Broadway, 14th Floor, Cambridge MA 02142, USA


[contact-form-7 404 "Not Found"]